AAPL   319.39 (-0.76%)
MSFT   181.61 (-0.67%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.45 (-0.71%)
NVDA   348.02 (-1.20%)
CGC   16.17 (-1.88%)
BABA   211.84 (+2.55%)
GE   6.99 (+3.40%)
TSLA   882.49 (-1.74%)
T   30.93 (+0.00%)
GILD   73.19 (-2.62%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
AAPL   319.39 (-0.76%)
MSFT   181.61 (-0.67%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.45 (-0.71%)
NVDA   348.02 (-1.20%)
CGC   16.17 (-1.88%)
BABA   211.84 (+2.55%)
GE   6.99 (+3.40%)
TSLA   882.49 (-1.74%)
T   30.93 (+0.00%)
GILD   73.19 (-2.62%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
AAPL   319.39 (-0.76%)
MSFT   181.61 (-0.67%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.45 (-0.71%)
NVDA   348.02 (-1.20%)
CGC   16.17 (-1.88%)
BABA   211.84 (+2.55%)
GE   6.99 (+3.40%)
TSLA   882.49 (-1.74%)
T   30.93 (+0.00%)
GILD   73.19 (-2.62%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
AAPL   319.39 (-0.76%)
MSFT   181.61 (-0.67%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.45 (-0.71%)
NVDA   348.02 (-1.20%)
CGC   16.17 (-1.88%)
BABA   211.84 (+2.55%)
GE   6.99 (+3.40%)
TSLA   882.49 (-1.74%)
T   30.93 (+0.00%)
GILD   73.19 (-2.62%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
Log in

NASDAQ:GNCAGenocea Biosciences Stock Price, Forecast & News

$2.66
-0.06 (-2.21 %)
(As of 06/2/2020 11:32 AM ET)
Add
Compare
Today's Range
$2.66
Now: $2.66
$2.85
50-Day Range
$1.82
MA: $2.36
$3.06
52-Week Range
$1.10
Now: $2.66
$11.28
Volume3,119 shs
Average Volume522,189 shs
Market Capitalization$73.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Read More
Genocea Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.89 per share

Profitability

Net Income$-38,950,000.00

Miscellaneous

Employees61
Market Cap$73.52 million
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

How has Genocea Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GNCA stock has increased by 45.4% and is now trading at $2.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Genocea Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genocea Biosciences.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Genocea Biosciences.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) released its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.11. View Genocea Biosciences' earnings history.

What price target have analysts set for GNCA?

4 equities research analysts have issued 1-year target prices for Genocea Biosciences' stock. Their forecasts range from $7.00 to $32.00. On average, they expect Genocea Biosciences' stock price to reach $16.33 in the next year. This suggests a possible upside of 514.0% from the stock's current price. View analysts' price targets for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:
  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (5/6/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019)

Has Genocea Biosciences been receiving favorable news coverage?

News coverage about GNCA stock has trended very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genocea Biosciences earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutGenocea Biosciences.

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 128,700 shares, a drop of 43.7% from the April 30th total of 228,400 shares. Based on an average daily trading volume, of 283,400 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.8% of the shares of the stock are short sold. View Genocea Biosciences' Current Options Chain.

Who are some of Genocea Biosciences' key competitors?

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
  • Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
  • Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
  • Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Who are Genocea Biosciences' major shareholders?

Genocea Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (26.14%), FNY Investment Advisers LLC (1.09%), Bank of New York Mellon Corp (0.07%) and WINTON GROUP Ltd (0.06%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri and Peter W Sonsini. View institutional ownership trends for Genocea Biosciences.

Which institutional investors are buying Genocea Biosciences stock?

GNCA stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, FNY Investment Advisers LLC, Bank of New York Mellon Corp, and WINTON GROUP Ltd. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri, and Peter W Sonsini. View insider buying and selling activity for Genocea Biosciences.

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $2.66.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $73.52 million. The biotechnology company earns $-38,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is www.genocea.com.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.